Answers are grounded in this paper and cite their sources.
Endothelium-derived relaxing factor (EDRF) and donors of nitric oxide (NO) (glyceryl trinitrate, SIN-1--a metabolite of molsidomine--S-nitroso-N-acetyl-penicillamine, and sodium nitroprusside) but not prostacyclin and its analog, iloprost, relax strips of rabbit aorta. Strips of human coronary artery also relax when exposed to NO donors and prostacyclin; in this artery, SIN-1 and iloprost exert additive but not synergistic relaxant action. In mildly activated human platelets and leukocytes, SIN-1 and iloprost have a synergistic suppressive action. A similar synergistic thrombolytic effect between NO and prostacyclin was observed in whole rabbit blood in interactions with rabbit aortic endothelium. These findings suggest that because of this cell-selective synergism between NO donors and prostacyclin analogs, the concomitant use of molsidomine and iloprost for the treatment of ischemic heart and peripheral vascular disease should be attempted.
No takes yet. Share an insight, caveat, or question.
Gryglewski et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: